Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/36451
Title: Efficacy of Sotrastaurin Plus Tacrolimus After de Novo Kidney Transplantation: Randomized, Phase II Trial Results
Authors: Russ, G. R.
Tedesco-Silva Junior, Hélio [UNIFESP]
Kuypers, D. R.
Cohney, S.
Langer, R. M.
Witzke, O.
Eris, J.
Sommerer, C.
von Zur-Muehlen, B.
Woodle, E. S.
Gill, J.
Ng, J.
Klupp, J.
Chodoff, L.
Budde, K.
Univ Adelaide
Universidade Federal de São Paulo (UNIFESP)
Katholieke Univ Leuven Hosp
Royal Melbourne Hosp
Semmelweis Univ
Univ Duisburg Essen
Royal Prince Alfred Hosp
Univ Heidelberg Hosp
Uppsala Univ
Univ Cincinnati
St Pauls Hosp
Novartis Pharmaceut
Novartis Pharma AG
Charite
Keywords: Efficacy
enteric-coated mycophenolic acid
kidney transplantation
sotrastaurin
tacrolimus
Issue Date: 1-Jul-2013
Publisher: Wiley-Blackwell
Citation: American Journal of Transplantation. Hoboken: Wiley-Blackwell, v. 13, n. 7, p. 1746-1756, 2013.
Abstract: Sotrastaurin, a novel immunosuppressant, blocks early T cell activation through protein kinase C inhibition. Efficacy and safety of sotrastaurin with tacrolimus were assessed in a dose-ranging non-inferiority study in renal transplant recipients. A total of 298 patients were randomized 1:1:1:1 to receive sotrastaurin 100 (n=77; discontinued in December 2011) or 200mg (n=73) b.i.d. plus standard tacrolimus (sTAC; 5-12ng/mL), sotrastaurin 300mg (n=75) b.i.d. plus reduced tacrolimus (rTAC; 2-5ng/mL) or enteric-coated mycophenolic acid (MPA) plus sTAC (n=73); all patients received basiliximab and corticosteroids. Composite efficacy failure (treated biopsy-proven acute rejectiongrade IA, graft loss, death or loss to follow up) rates at Month 12 were 18.8%, 12.4%, 10.9% and 14.0% for the sotrastaurin 100, 200 and 300mg, and MPA groups, respectively. the median estimated glomerular filtration rates were 55.7, 53.3, 64.9 and 59.2mL/min, respectively. Mean heart rates were faster with higher sotrastaurin doses and discontinuations due to adverse events and gastrointestinal adverse events were more common. Fewer patients in the sotrastaurin groups experienced leukopenia than in the MPA group (1.3-5.5% vs. 16.5%). Sotrastaurin 200 and 300mg had comparable efficacy to MPA in prevention of rejection with no significant difference in renal function between the groups.
URI: http://repositorio.unifesp.br/handle/11600/36451
ISSN: 1600-6135
Other Identifiers: http://dx.doi.org/10.1111/ajt.12251
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.